Compare APA & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APA | HALO |
|---|---|---|
| Founded | 1954 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.8B |
| IPO Year | 2021 | 2001 |
| Metric | APA | HALO |
|---|---|---|
| Price | $43.77 | $62.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 22 | 11 |
| Target Price | $29.82 | ★ $78.18 |
| AVG Volume (30 Days) | ★ 9.0M | 1.3M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ 75.77 | N/A |
| EPS | ★ 3.99 | 2.56 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | N/A | $28.24 |
| Revenue Next Year | N/A | $12.79 |
| P/E Ratio | ★ $11.14 | $24.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.58 | $47.50 |
| 52 Week High | $44.54 | $82.22 |
| Indicator | APA | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 83.54 | 32.28 |
| Support Level | $22.73 | $61.23 |
| Resistance Level | N/A | $65.40 |
| Average True Range (ATR) | 1.49 | 1.52 |
| MACD | 0.69 | -0.01 |
| Stochastic Oscillator | 83.52 | 10.49 |
APA Corp is an independent exploration and production company. It develops, and produces crude oil, natural gas, and natural gas liquids. The Company's business has oil and gas operations in three geographic areas: the United States (U.S.), Egypt, and offshore the U.K. in the North Sea (North Sea). APA also has active development, exploration, and appraisal operations ongoing in Suriname, as well as exploration interests in Uruguay, Alaska, and other international locations.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.